Alzecure Pharma: Comment on Study Results
Research Note
2021-04-20
07:20
Yesterday, Alzecure Pharma announced positive results from its phase 1b study with drug candidate ACD440 in neuropathic pain. Redeye gives its first reflections to this news and raises Base Case.
AH
Anders Hedlund
Disclosures and disclaimers